Literature DB >> 25305091

Outpatient or inpatient treatment for acute pulmonary embolism: a retrospective cohort study of 439 consecutive patients.

Sebastian Werth1, Virginia Kamvissi, Thoralf Stange, Eberhard Kuhlisch, Norbert Weiss, Jan Beyer-Westendorf.   

Abstract

Current guidelines consider outpatient treatment as an option for low-risk pulmonary embolism (PE), and risk assessment tools such as the HESTIA criteria can be used to identify PE patients who could feasibly be treated in an outpatient setting. Little is known about what proportion of patients in daily care this would comprise, and, in these patients, outcome data outside of clinical trials are scarce. To assess the proportion of PE patients receiving outpatient early discharge or in-hospital therapy, evaluate differences in patient characteristics between these subgroups and to assess clinical outcomes at 6 months. Monocentric, retrospective cohort study in 439 consecutive patients undergoing outpatient, early-discharge or in-hospital treatment for PE. Outcome data on recurrent VTE, pulmonary hypertension or death were collected from routine follow-up visits 6 months after VTE diagnosis. PE patients were treated as outpatient (OP; n = 49; 11.2 %); early-discharge (ED; n = 62; 14.1 %) or in-hospital (IH; n = 328; 74.7 %). Median duration of hospital stay in the ED and IH groups were 1 (IQR: 1) day and 9 (IQR: 7) days, respectively. Outcome event rates at 6 months were 3.9 % for recurrent VTE (95 % CI 2.3-6.1, similar between groups), 5.2 % for pulmonary hypertension (95 % CI 3.3-7.8, similar between groups) and 10.7 % for mortality (95 % CI 8.0-14.0). Mortality was significantly higher in IH patients (14.0 %; 95 % CI 10.5-18.3) compared to OP (0 %; 95 % CI 0.0-7.3) or ED (1.6 %; 95 % CI 0.0-8.7) patients. Mortality risk factors were high-risk ESC category (OR: 5.7), paraneoplastic VTE (OR: 3.0), need for oxygen supplementation (OR: 5.2), diabetes (OR: 2.5), age (OR per additional year: 1.1) and elevated INR (OR per 0.1 point increase: 1.5). No difference in the treatment groups for pulmonary hypertension during follow-up was found. Independent risk factors were thrombophilia (OR: 8.43), signs of right ventricular strain in baseline ECG (OR: 6.64) or echocardiography (RVESP > 40 mmHg OR: 2.99). 32 % of the OP or ED patients had at least one criterion of the HESTIA score that would have excluded them from outpatient treatment. In daily care, treating PE in an almost exclusively outpatient setting seems feasible and safe for up to 25 % of all PE patients. The HESTIA criteria seem to exclude up to 30 % of patients for whom outpatient or early-discharge treatment seems feasible and safe.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25305091     DOI: 10.1007/s11239-014-1141-y

Source DB:  PubMed          Journal:  J Thromb Thrombolysis        ISSN: 0929-5305            Impact factor:   2.300


  28 in total

Review 1.  Risk factors for chronic thromboembolic pulmonary hypertension.

Authors:  N H Kim; I M Lang
Journal:  Eur Respir Rev       Date:  2012-03-01

2.  High prevalence of detectable deep venous thrombosis in patients with acute pulmonary embolism.

Authors:  P Girard; D Musset; F Parent; S Maitre; C Phlippoteau; G Simonneau
Journal:  Chest       Date:  1999-10       Impact factor: 9.410

3.  Eligibility for home treatment of deep vein thrombosis: a prospective study in 202 consecutive patients.

Authors:  T Schwarz; B Schmidt; J Beyer; H E Schröder; S M Schellong
Journal:  J Vasc Surg       Date:  2001-12       Impact factor: 4.268

4.  Rates of initial and recurrent thromboembolic disease among patients with malignancy versus those without malignancy. Risk analysis using Medicare claims data.

Authors:  N Levitan; A Dowlati; S C Remick; H I Tahsildar; L D Sivinski; R Beyth; A A Rimm
Journal:  Medicine (Baltimore)       Date:  1999-09       Impact factor: 1.889

5.  A comparison of the original and simplified Pulmonary Embolism Severity Index.

Authors:  Carmen Venetz; David Jiménez; Marie Mean; Drahomir Aujesky
Journal:  Thromb Haemost       Date:  2011-06-28       Impact factor: 5.249

6.  Interobserver agreement of complete compression ultrasound for clinically suspected deep vein thrombosis.

Authors:  Thomas Schwarz; Benjamin Schmidt; Barbara Schmidt; Sebastian M Schellong
Journal:  Clin Appl Thromb Hemost       Date:  2002-01       Impact factor: 2.389

7.  Derivation and validation of a prognostic model for pulmonary embolism.

Authors:  Drahomir Aujesky; D Scott Obrosky; Roslyn A Stone; Thomas E Auble; Arnaud Perrier; Jacques Cornuz; Pierre-Marie Roy; Michael J Fine
Journal:  Am J Respir Crit Care Med       Date:  2005-07-14       Impact factor: 21.405

Review 8.  Is it time for home treatment of pulmonary embolism?

Authors:  Mareike Lankeit; Stavros Konstantinides
Journal:  Eur Respir J       Date:  2012-04-10       Impact factor: 16.671

9.  Glycemia (hemoglobin A1c) and incident venous thromboembolism in the Atherosclerosis Risk in Communities cohort study.

Authors:  Elizabeth J Bell; Elizabeth Selvin; Pamela L Lutsey; Vijay Nambi; Mary Cushman; Aaron R Folsom
Journal:  Vasc Med       Date:  2013-10       Impact factor: 3.239

10.  Guidelines on the diagnosis and management of acute pulmonary embolism: the Task Force for the Diagnosis and Management of Acute Pulmonary Embolism of the European Society of Cardiology (ESC).

Authors:  Adam Torbicki; Arnaud Perrier; Stavros Konstantinides; Giancarlo Agnelli; Nazzareno Galiè; Piotr Pruszczyk; Frank Bengel; Adrian J B Brady; Daniel Ferreira; Uwe Janssens; Walter Klepetko; Eckhard Mayer; Martine Remy-Jardin; Jean-Pierre Bassand
Journal:  Eur Heart J       Date:  2008-08-30       Impact factor: 29.983

View more
  6 in total

1.  [Acute pulmonary embolism: still a diagnostic and therapeutic challenge?]

Authors:  R Felgendreher; D Härtel; J Brockmeier; K Bramlage; T Aschenbrenner; J Götz; P Bramlage; U Tebbe
Journal:  Med Klin Intensivmed Notfmed       Date:  2016-11-02       Impact factor: 0.840

2.  Expression of microRNA-514a-5p and its biological function in experimental pulmonary thromboembolism.

Authors:  Yuanyuan Sun; Xingguo Zhang; Hua Gao; Mingjie Liu; Qi Cao; Xinyang Kang; Yusheng Wang; Ling Zhu
Journal:  Am J Transl Res       Date:  2019-09-15       Impact factor: 4.060

3.  The design and implementation of a new surveillance system for venous thromboembolism using combined active and passive methods.

Authors:  Aaron M Wendelboe; Janis Campbell; Micah McCumber; Dale Bratzler; Kai Ding; Michele Beckman; Nimia Reyes; Gary Raskob
Journal:  Am Heart J       Date:  2015-06-11       Impact factor: 4.749

Review 4.  Cardiovascular Involvement in COVID-19: What Sequelae Should We Expect?

Authors:  Maria Vincenza Polito; Angelo Silverio; Michele Bellino; Giuseppe Iuliano; Marco Di Maio; Carmine Alfano; Patrizia Iannece; Nicolino Esposito; Gennaro Galasso
Journal:  Cardiol Ther       Date:  2021-06-30

Review 5.  Reducing the hospital burden associated with the treatment of pulmonary embolism.

Authors:  W Frank Peacock; Adam J Singer
Journal:  J Thromb Haemost       Date:  2019-04-01       Impact factor: 5.824

6.  Comprehensive Outpatient Management of Low-Risk Pulmonary Embolism: Can Primary Care Do This? A Narrative Review.

Authors:  David R Vinson; Drahomir Aujesky; Geert-Jan Geersing; Pierre-Marie Roy
Journal:  Perm J       Date:  2020-03-13
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.